Kowa Company Limited

Juridical Foundation the Chemo-sero-therapeutic Research Institute

The Chemo-sero-therapeutic Research Institute

Toshiyuki Edano

Yukihiro Sato

Kimiyuki Shibuya

Katsumi Kawamine

Mitsuteru Hirata

Chiyoka Ozaki

Toru Miura

Tadaaki Ohgiya

Takahiro Kitamura

Masami Shiratsuchi

Toshihiro Nakashima

Masao Ohkuchi

Tomoyuki Koshi

Tsukasa Nishihara

Takumi Sasaki

Atsuko Sakata

Souhei Tanabe

Kazuhiko Kimachi

Sumiyo Takemoto

Shigeki Kuwata

Tsukasa c/o Juridical Foundation The Nishihara

Sumiyo c/o Juridical Foundation The Takemoto

Toshihiro c/o Juridical Foundation The Nakashima

Takumi c/o Juridical Foundation The Sasaki

Takumi c/o Juridical Foundation Sasaki

Toshihiro c/o Juridical Foundation Nakashima

Kazuhiko c/o Juridical Foundation Kimachi

Shigeki c/o Juridical Foundation Kuwata

Tsukasa c/o Juridical Foundation Nishihara

A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.

Modified SEB and prophylactics/remedies for immunopathy containing the same

A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.

Protease-resistant modified SEB and vaccine containing the same

The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) 

Amide compounds and medications containing the same technical field

Amide compounds and medications containing the same

The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof.(In the formula,is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).

Cyclic diamine compounds and medicine containing the same

The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I)

Anilide compounds and pharmaceutical compositions comprising them

Anilide compounds and drugs containing the same

Anilide compounds, including use thereof in ACAT inhibitition

Growing community of inventors

Kawagoe, Japan

Toshiyuki Edano